Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Flucitasone furoate (Avamys) | Approved for use in children and adults. Previous APC decision reviewed in December 2015. |
|
 |
Flucitasone inhaler (Flixotide) evohaler 125 / Fluticasone accuhaler 250 | For paediatric use only |
|
|
Flucitasone inhaler (Flixotide) evohaler 50 / Fluticasone accuhaler 50, 100 | For paediatric use only |
|
|
Flucitasone propionate and azelastine (Dymista®) | Third line option for adults and children over 12 with moderate to severe allergic rhinitis who have failed ot respond to a steroid nasal spray with the addition of an oral antihistamine. Follow APC treatment algorithm. |
|
 |
Flunarazine tablets | Not licensed in the UK. Licensed in Europe and Ireland - preventative management in primary headache. |
|
|
Fluocinolone acetonide 0.025% (Synalar 1 in 10 dilution®) | Mild - for use in paediatrics |
|
|
Fluorometholone 0.1% eye drops (5ml) | Specialist ophthalmologist recommendation |
|
|
Fluorouracil injection |
|
For hospital use only |
|
Flupentixol decanoate injection | Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion). |
|
|
Fluphenazine decanoate injection | Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion). |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
